NasdaqCM - Nasdaq Real Time Price USD

Synaptogenix, Inc. (SNPX)

2.5200

+0.0200

+(0.80%)

As of 9:35:41 AM EDT. Market Open.

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 mi

PR Newswire 4 months ago

SNPX
+0.80%
Synaptogenix Announces $5.0 Million Financing

Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common sto

PR Newswire 7 months ago

SNPX
+0.80%
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Pate

PR Newswire 9 months ago

SNPX
+0.80%
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).

PR Newswire 10 months ago

SNPX
+0.80%

Performance Overview

Return	SNPX	S&P 500 (^GSPC)
YTD	-27.38%	-0.25%
1-Year	-46.50%	+10.53%
3-Year	-97.84%	+45.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Synaptogenix, Inc. (SNPX)

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Performance Overview